Stremmel W, Vural H, Evliyaoglu O, et al. - A meta-analysis of three randomized controlled trials was performed to evaluate 30% phosphatidylcholine (PC)-containing lecithin in a delayed intestinal release formulation for treatment efficacy of ulcerative colitis. Via RevMan 5.3 software, a meta-analysis of the three studies was conducted. Researchers computed the odds ratio and 95% Cl for remission, clinical and endoscopic improvement, histology, and life quality. The study included a total of 160 patients with ulcerative colitis. The results demonstrated that, in patients with ulcerative colitis, a 30% PC containing lecithin in delayed intestinal release formulation improves clinical and endoscopic outcomes, histologic activity, and quality of life, and all effects were significant over placebo. The lack of adverse events is an important consideration for the patients.